Dendreon Corporation was founded
In 1992, Dendreon was founded, and its lead product, Provenge, was an immunotherapy for prostate cancer. Dendreon filed…
US Senator Alan Cranston underwent state-of-the-art procedure at Stanford University Hospital to attack his prostate cancer
In 1991, U.S. Senator Alan Cranston (D-Calif.) underwent a state-of-the-art procedure at Stanford University Hospital to attack his…
William J Catalona began a study that established the PSA blood test as prostate cancer screening tool
In 1989, researcher William J. Catalona, MD of Washington University – St. Louis began a study that established…
FDA approved Hybritech antibody test for prostate cancer – a first
In February 1986, the U.S. Food and Drug Administration (FDA) approved Hybritech’s Tandem-R PSA assay (P850048) with calibration…
The Wistar Institute was designated a National Cancer Institute Cancer Center
In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic researchï¾—a distinction it…
Last remaining source of the Hoxsey cancer treatment was eliminated by a federal court order
On Sept. 21, 1960, FDA officials announced the last remaining major source of the discredited Hoxsey cancer treatment…
Charles Huggins discovered that blocking male hormones could cause regression of prostate tumors
In 1941, Charles Huggins discovers that blocking male hormones (by removal of the testicles or administration of estrogens)…